Collaborations and Alliances

Building great relationships

In Europe we have forged a number of collaborations with other pharmaceutical companies and organisations that are equally committed to delivering pioneering treatments to patients as quickly as possible. These relationships include:
  • Akebia Therapeutics, Inc.: a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor biology
  • Bristol-Myers Squibb: a global biopharmaceutical company involved in the co-promotion of a treatment for chronic myeloid leukaemia in some European companies
  • Lundbeck: a Danish pharmaceutical company with a shared research interest in neuroscience, with a particular focus on Alzheimer’s disease, depression, Parkinson’s disease and schizophrenia. Otsuka and Lundbeck signed a global alliance agreement in 2011 to collaborate on the development and commercialisation of medicines to help patients with CNS disorders. This ‘horizontal alliance’ aims to create long-term growth and to develop new treatments to improve the lives of patients with psychiatric and neurological disorders
  • Proteus Digital Health Inc.: based in California, developing a cutting-edge feedback system through which wearable and ingestible sensors provide patients, carers and healthcare professionals, with a database of detailed information, such as when a medication has been taken and activity and rest patterns. The aim is to help patients better manage their conditions and to help clinicians provide more effective care when using new medicines currently being developed by Otsuka. This new frontier science is in keeping with our philosophy: ‘Otsuka-people creating new products for better health worldwide’.
We also acquire companies that can extend our commitment to develop in areas where there are unmet medical needs, enabling us to add value. For example:
  • Astex (Astex Pharmaceuticals, Inc and Astex Therapeutics Ltd.): focused on innovative drug discovery and development for cancer and diseases of the central nervous system. Astex’s drug discovery research headquarters are located in the UK, housing drug discovery research and preclinical development departments and the company’s clinical development headquarters are located in the San Francisco Bay area, USA, housing clinical, regulatory, and manufacturing and quality assurance departments. Click here to view more information about Astex Pharmaceuticals.
  • Avanir Pharmaceuticals Inc.: a biopharmaceutical company focused on developing treatments for patients with central nervous system disorders
Our collaborations are not restricted to the companies listed above – this is just a small snapshot of some of the relationships that we have built. We collaborate with many pharmaceutical companies and other organisations helping to deliver medicines to our European patients, and look forward to continuing to do so.

Date of preparation: February 2018

Reference OPEL/1017/GEN/1134f

“Otsuka’s approach is to foster horizontal alliances with multiple companies. Work well together, win together. If we succeed, they succeed.”Ole Vahlgren, CEO & President, Otsuka Pharmaceutical Europe